This section contains a detailed bibliography of clinical data for afatinib* and nintedanib**, including trials, subgroup analyses, real-world data, case studies and review articles. Please use the filters to find publications in your area of interest. Alternatively, please select the compound of interest to group articles together and introduce further filter options for tumour entity, setting and patient population.

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

Showing 1-10 of 281 Articles

Title	Citation	Focus area
PIVOTAL TRIAL DATA FOR LUX-LUNG 3 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations	Sequist LV, et al. J Clin Oncol 2013;31(27):3327-3334		1 2 3 A
LUME LUNG 1 PIVOTAL DATA TRIAL Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial	Reck M, et al. Lancet Oncol 2014;15(2):143-155	Non-small cell lung cancer first line epidermal growth factor mutation-positive	1 2 3 A
PIVOTAL TRIAL DATA Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations view article	Yang JC-H, et al. J Clin Oncol 2013;31(27):3342-3350	Non-small cell lung cancer	1 2 3 A
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases view article	Schuler M, et al. J Thorac Oncol 2016;11(3):380-90	Non-small cell lung cancer first line epidermal growth factor mutation-positive	1 2 3 A
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials view article	Yang JC-H, et al. Ann Oncol 2016;27(11):2103-2110	Non-small cell lung cancer	1 2 3 A
Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6 view article	Fein L, et al. J Thorac Oncol 2016;11(Suppl 10):S202-203	Non-small cell lung cancer first line epidermal growth factor mutation-positive	1 2 3 A
First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials view article	Schuler M, et al. Eur J Cancer 2017;72(Suppl 1):S176-S177	Non-small cell lung cancer first line epidermal growth factor mutation-positive	1 2 3 A
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 view article	Wu Y-L, et al. Br J Cancer 2017;116:175-185	Non-small cell lung cancer first line epidermal growth factor mutation-positive	1 2 3 A
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 view article	Yang JC-H, et al. Lancet Oncol 2015;16(7):830–838	Non-small cell lung cancer first line epidermal growth factor mutation-positive	1 2 3 A
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 view article	Kato T, et al. Cancer Sci 2015;106(9):1202-1211	Non-small cell lung cancer second line	1 2 3 A

WELCOME TO THE INONCOLOGY WEBSITE FOR INTERNATIONAL HEALTHCARE PROFESSIONALS OUTSIDE THE UNITED STATES OF AMERICA AND THE UNITED KINGDOM

Article library

Filter by:

Disclaimer